{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T14:45:40Z","timestamp":1761662740887},"reference-count":24,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2009,5,6]],"date-time":"2009-05-06T00:00:00Z","timestamp":1241568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2009,9]]},"abstract":"<jats:p><jats:bold>Objectives\n\t\t\t\t\t<\/jats:bold> We reviewed the safety and efficacy of nevirapine (NVP)\u2010based therapy in all patients initiating NVP\u2010containing combined antiretroviral therapy [cART (\u22653 drugs)] in our clinic since 1994.<\/jats:p><jats:p><jats:bold>Methods\n\t\t\t\t\t<\/jats:bold> Patient characteristics and laboratory values from the start of the NVP\u2010based cART regimen to the last available follow\u2010up or to NVP discontinuation were retrieved from an observational database.<\/jats:p><jats:p><jats:bold>Results\n\t\t\t\t\t<\/jats:bold> Five hundred and seventy\u2010three patients were treated with NVP\u2010based cART for a median of 18.4 (range 0.1\u2013128.8) months. The 1\u2010year cumulative estimated probability of discontinuing NVP\u2010containing regimens for toxicity was 0.203. Only 1.9% developed a grade 3 alanine aminotransferase (ALT) elevation. Significant increases in high\u2010density lipoprotein cholesterol were observed up to month 12 except in treatment\u2010na\u00efve patients, where the increase was limited to 3 months. Discontinuation because of cutaneous reaction was predicted independently by female gender [Hazard Ratio (HR) 3.21, <jats:italic>P<\/jats:italic>&lt;0.001] and Centers for Disease Control class C (HR 0.50, <jats:italic>P<\/jats:italic>=0.012). Discontinuation because of liver toxicity was predicted independently by anti\u2010hepatitis C virus positivity (HR 3.84, <jats:italic>P<\/jats:italic>&lt;0.001). In patients starting NVP\u2010containing cART with undetectable viral loads, the 5\u2010year estimated probability of viral load &gt;400 HIV\u20101 RNA copies\/mL was 0.34.<\/jats:p><jats:p><jats:bold>Conclusions\n\t\t\t\t\t<\/jats:bold> Long\u2010term follow\u2010up with an NVP\u2010containing cART showed a low rate of discontinuation caused by liver toxicity and the maintenance of virological suppression in patients switched with undetectable viral loads.<\/jats:p>","DOI":"10.1111\/j.1468-1293.2009.00713.x","type":"journal-article","created":{"date-parts":[[2009,5,7]],"date-time":"2009-05-07T02:41:11Z","timestamp":1241664071000},"page":"461-469","source":"Crossref","is-referenced-by-count":8,"title":["Long\u2010term follow\u2010up of nevirapine\u2010treated patients in a single\u2010centre cohort"],"prefix":"10.1111","volume":"10","author":[{"given":"M","family":"Colafigli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Di Giambenedetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Bracciale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Fanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Prosperi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Cauda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,8,2]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1701568"},{"key":"e_1_2_5_3_2","first-page":"1253","article-title":"Comparison of first\u2010line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine","volume":"363","author":"Van Leth F","year":"2004","journal-title":"a randomised open-label trial, the 2NN Study"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021589"},{"key":"e_1_2_5_5_2","first-page":"S40","article-title":"Efficacy and durability of nevirapine in antiretroviral drug na\u00efve patients","volume":"34","author":"Lange Joep MA.","year":"2003","journal-title":"J AIDS"},{"key":"e_1_2_5_6_2","unstructured":"DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents [a working group of the Office of AIDS Research Advisory Council (OARAC)]. Guidelines for the Use of Antiretroviral Agents in HIV\u20101\u2010infected Adults and Adolescents. Available at:http:\/\/aidsinfo.nih.gov(accessed 28 October 2008)."},{"key":"e_1_2_5_7_2","doi-asserted-by":"crossref","unstructured":"ClumeckN PozniakA RaffiF European Aids Clinical Society (EACS) Executive Committee.Guidelines for the Clinical Management and Treatment of HIV Infected Adults in Europe 2007. Available at:http:\/\/www.eacs.eu(accessed 15 July 2008).","DOI":"10.1111\/j.1468-1293.2007.00533.x"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200309011-00004"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200107060-00007"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1086\/428093"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200309011-00005"},{"key":"e_1_2_5_12_2","first-page":"538","article-title":"Hepatotoxicity associated with nevirapine use","volume":"35","author":"Sloas Baylor M","year":"2004","journal-title":"J AIDS"},{"key":"e_1_2_5_13_2","first-page":"431","article-title":"Long\u2010term assessment of nevirapine\u2010containing highly active antiretroviral therapy in antiretroviral\u2010na\u00efve HIV\u2010infected patients","volume":"7","author":"Reliquet V","year":"2006","journal-title":"3-year follow-up of the VIRGO Study"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200104130-00020"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.1.74"},{"key":"e_1_2_5_16_2","first-page":"569","article-title":"Reasons for discontinuation of nevirapine\u2010containing HAART","volume":"59","author":"Maggiolo F","year":"2007","journal-title":"results from an unselected population of a large clinical cohort"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2008.00513.x"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1086\/423385"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2006.22.321"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl524"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200107060-00007"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1086\/427216"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282170a9d"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200309011-00012"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3280121ab1"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2009.00713.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2009.00713.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T16:19:23Z","timestamp":1696868363000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2009.00713.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,2]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["10.1111\/j.1468-1293.2009.00713.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2009.00713.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,2]]}}}